Autosomal Dominant Polycystic Kidney Disease (ADPKD)
TITLE
DOWNLOAD
OCTOBER 2026 | A Phase 1a/1b (PINACLE-1) Part B: single ascending dose in patients with autosomal dominant polycystic disease (ADPKD)
AUGUST 2026 | A Phase 1 Study of PYC-003, a Peptide-Oligonucleotide Conjugate Designed to Increase PC1 Expression in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
MARCH 2026 | PINACLE-1: A Phase 1 Clinical Trial of PYC-003 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SEPTEMBER 2025 | A Phase 1a Clinical Trial of PYC-003 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)